GSKGlaxoSmithKlineSigning up patients
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Neoplasms, Prostate
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 684 (planned)
- Started
- Sep 1, 2026
- Main results expected
- Dec 5, 2029
- Fully finished
- Dec 5, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Radiographic Progression-Free Survival (rPFS) per PCWG3 by BICR
Measured over: Up to approximately 169 weeks
Overall Survival (OS)
Measured over: Up to approximately 169 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07802704 · record last updated 2026-10-02 · checked 2026-11-09 15:47 UTC